Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes

OBJECTIVE
To investigate the pharmacokinetic and pharmacodynamic properties and safety of a novel formulation of insulin aspart (AT247) versus two currently marketed insulin aspart formulations (NovoRapid [IAsp] and Fiasp [faster IAsp]).

RESEARCH DESIGN AND METHODS
This single-center, randomized, double-blind, three-period, crossover study was conducted in 19 men with type 1 diabetes, receiving single dosing of trial products (0.3 units/kg) in a random order on three visits. Pharmacokinetics and pharmacodynamics were assessed during a euglycemic clamp lasting up to 8 h.

RESULTS
Onset of insulin appearance was earlier for AT247 compared with IAsp (−12 min [95% CI −14; −8], P = 0.0004) and faster IAsp (−2 min [−5; −2], P = 0.0003). Onset of action was accelerated compared with IAsp (−23 min [−37; −15], P = 0.0004) and faster IAsp (−9 min [−11; −3], P = 0.0006). Within the first 60 min, a higher exposure was observed for AT247 compared with IAsp by the area under the curve (AUC) glucose infusion rate (GIR) from 0 to 60 min (AUCAsp0−60min: treatment ratio vs. IAsp 2.3 [1.9; 2.9] vs. faster IAsp 1.5 [1.3; 1.8]), which was underpinned by a greater early glucose-lowering effect (AUCGIR,0−60min: treatment ratio vs. IAsp 2.8 [2.0; 5.5] vs. faster IAsp 1.7 [1.3; 2.3]). Furthermore, an earlier offset of exposure was observed for AT247 compared with IAsp (−32 min [−58; −15], P = 0.0015) and faster IAsp (−27 min [−85; −15], P = 0.0017), while duration of the glucose-lowering effect, measured by time to late half-maximum effect, did not differ significantly.

CONCLUSIONS
AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with IAsp and faster IAsp. It therefore represents a promising candidate in the pursuit for second-generation prandial insulin analogs to improve postprandial glycemic control.
Rapid-acting insulin analogs, such as insulin aspart, insulin glulisine, and insulin lispro, play a substantial role in modern clinical management of both type 1 and type 2 diabetes (1). Purposely designed to achieve faster subcutaneous absorption than regular human insulin, rapid-acting analogs provide an earlier onset and shorter duration of action and should thus improve patient convenience (administration closer to or at mealtimes), optimize postprandial glycemic control, and reduce the risk of late postprandial hypoglycemia (2–4). In line with current labeling (5–7), rapid-acting analogs have to be administered within 15 min before or up to 20 min after starting a meal. However, recent reviews indicate that an injection–meal interval of 15–20 min before a meal is still required to best meet postprandial insulin needs (8,9). For practical reasons, however, most people with diabetes use a short or no premeal interval or only inject postmeal, leading to suboptimal outcomes (10–13).

Further adjustments in pharmaceutical formulations have led to a new generation of rapid-acting insulin analogs with even more accelerated action profiles (9,14,15) to better resemble physiological prandial insulin action. Of the various initial prototypes, BioChaperone Lispro (Adocia) (16,17) is entering phase 3 trials and ultrarapid lispro (URLi or LY900014; Eli Lilly) (18,19) has recently been approved by the European Medicines Agency. Faster insulin aspart (Fiasp; Novo Nordisk, Bagsvaerd, Denmark) (20,21) is the first analog that has been approved in the U.S., Canada, Australia, and the European Union. It is already part of multiple daily injection regimens and insulin pump therapy in clinical practice (22,23) and has recently been applied in fully closed-loop insulin therapy (24).

A novel formulation of insulin aspart (AT247; Arecor Limited, Little Chesterford, U.K.) is currently under development and designed to provide an enhanced time-action profile after subcutaneous injection. AT247 contains a hexameric form of insulin aspart and an excipient that accelerates the rate of insulin absorption from the subcutaneous injection site. The excipient binds calcium ions, and the proposed mechanism for the accelerated absorption rate is increased tissue permeability through a transient disruption of the calcium-dependent cell adhesion in the injection site via reversible interactions with the calcium-cadherin complex at the cell surface (25). In addition, AT247 contains a stabilizing surfactant and standard preservatives (phenol and m-cresol).

The current study investigated the pharmacokinetic and pharmacodynamic properties as well as the safety of AT247 versus two currently marketed insulin aspart formulations (NovoRapid [IAsp] and Fiasp [faster IAsp]) in a euglycemic clamp setting in men with type 1 diabetes.

**RESEARCH DESIGN AND METHODS**

**Trial Design**

This single-center (Medical University of Graz), randomized, double-blind, three-period, crossover phase 1 trial evaluated the pharmacokinetics, pharmacodynamics, and safety of a novel formulation of insulin aspart (AT247) compared with IAsp and faster IAsp in men with type 1 diabetes. The trial protocol was reviewed and approved by the local health authority (Austrian Federal Office for Safety in Health Care, Vienna, Austria) and by the independent ethics committee of the Medical University of Graz (No. 31-201 ex 18/19). The trial was registered at ClinicalTrials.gov (NCT03959514) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (International Conference on Harmonization). All participants were recruited based on the database of the study site and gave written informed consent before any trial-related activities were initiated.

**Participants**

Eligible participants were men aged 18–64 years (both inclusive), diagnosed with type 1 diabetes for at least 12 months, receiving treatment with multiple daily insulin injections or insulin pump therapy for at least 12 months with total insulin dose <1.2 units/kg/day and bolus insulin dose <0.7 units/kg/day. Participants were also required to have a BMI of 18.5–35.0 kg/m² (both inclusive), glycated hemoglobin (HbA₁c) ≥8.5% (≥69 mmol/mol), and fasting C-peptide ≥0.3 nmol/L. Key exclusion criteria were clinically significant concomitant diseases, clinically significant abnormal values in clinical laboratory screening tests, current treatment with drugs that might interfere with glucose metabolism, significant history of alcoholism or drug abuse, smoking more than five cigarettes per day, and a history of severe allergies to medications or foods. Eligibility was determined on the screening visit, and eligibility for continuation was confirmed the day before trial product administration of dosing visit 1.

**Procedures**

The trial consisted of an informed consent visit, a screening visit, three dosing visits (separated by a 3- to 15-day washout period to minimize carryover effects), and a follow-up visit. The random allocation sequence was generated using an interactive web response system (https://www.randomizer.at) by staff with no other involvement in the trial. Permuted block randomization with a block size of six was used. On the day of the trial product administration on dosing visit 1, participants were randomly assigned with equal allocation to one of six treatment sequences (Supplementary Fig. 1). Unblinded staff, who were not involved in any other trial activities, ensured the correct treatment allocation and dispensing of trial products on the dosing visits. They transferred all trial products into 1-mL disposable syringes by using the four-eye principle. To ensure double-blinding, the trial products were then administered by blinded investigators.

On the three dosing visits, participants received a single dose of 0.3 units/kg AT247 (100 units/ml) (Arecor Limited), IAsp (NovoRapid 100 units/ml) (Novo Nordisk), or faster IAsp (Fiasp 100 units/ml) (Novo Nordisk). All trial products were administered subcutaneously into a lifted skin fold of the abdominal wall around the umbilicus. To ensure a proper basal insulin washout, participants treated with ultralong-acting and long-acting insulin analogs were switched to NPH insulin (Insulatard; 100 units/ml) in a 3-mL FlexPen (Novo Nordisk) 72 and 48 h before trial product administration, respectively, before each dosing visit. Use of intermediate-acting and short-acting insulin products was terminated 18 and 14 h before dosing, respectively.

On each dosing visit, participants arrived at the trial site at 6:00 P.M. the day before trial product administration and were served a standardized meal. Participants started fasting at 8:00 P.M. The pharmacodynamics of trial products were assessed by the euglycemic clamp technique, with an overnight run-in period starting at 10:00 P.M. Participants using continuous subcutaneous insulin infusion had to switch off their insulin pump, and all participants received a variable intravenous infusion of human
insulin (40 units Actrapid 100 units/mL [Novo Nordisk] in 99.6 mL saline) or glucose (20%) [Fresenius Kabi, Bad Homburg, Germany] to obtain a plasma glucose (PG) clamp target level of 5.5 mmol/L (100 mg/dL). The trial product was administered between 8:00 A.M. and 10:00 A.M. on the next day after PG had stabilized for at least 1 h without glucose infusion. The rate of insulin infusion was reduced gradually during the last 15 min and completely stopped 5 min before dosing. After trial product administration and a decrease in PG by 0.3 mmol/L (5 mg/dL) a variable intravenous glucose infusion was initiated to keep PG constant at the clamp target. PG was measured in 2- to 30-min intervals throughout the clamp, and the glucose infusion rate (GIR) was recorded as required. The clamp continued for 8 h after dosing but was terminated earlier if PG was consistently >111 mmol/L (200 mg/dL) without glucose infusion for at least 30 min. The quality of the conducted glucose clamp was assessed (26) for each trial product is shown in Supplementary Fig. 2 and Supplementary Table 1. Blood sampling for pharmacokinetics and safety clinical laboratory evaluations as well as all additional safety assessments were performed frequently at prespecified time intervals according to the protocol.

Assessments
Blood samples were analyzed for total free serum insulin using a validated, iso-insulin ELISA (Mercodia, Uppsala, Sweden) with a lower limit of quantification (LLOQ) of 6.4 µU/L. Because this assay is 100% cross-reactive to the human insulin administered during the clamp run-in period, free serum human insulin was additionally determined in samples up to 40 min postdose using a validated, human insulin–selective ELISA (Mercodia) with an LLOQ of 3.2 µU/L. These results were used to correct the total insulin values to obtain insulin aspart data. PG concentrations during the euglycemic clamp were measured by a glucose analyzer (Super Gl 2; Dr. Müller Gerätebau GmbH, Freital, Germany).

Safety assessments included physical examinations, vital signs, electrocardiograms, and clinical laboratory evaluations as well as reporting of disease-related and adverse events (AEs) such as hypoglycemia, injection site reactions, and hypersensitivity reactions. Hypoglycemic episodes were categorized by severity (severe, documented symptomatic, and asymptomatic) according to the American Diabetes Association (27).

End Points
The primary end point was the area under the curve (AUC) for GIR from 0 to 60 min (AUCGIR,0–60min). Secondary pharmacodynamic end points included AUC for GIR of various time intervals (AUCGIR,0–16min, AUCGIR,0–30min, AUCGIR,0–90min, AUCGIR,0–2h, and AUCGIR,0–8h), maximum GIR (GIRmax), time to GIRmax (tGIRmax), time to onset of action (time from trial product administration until PG has declined by 0.3 mmol/L), and time to 50% of GIRmax (t50%GIRmax and tLate50%GIRmax where t is the first and tLate is the last time point where GIR >50% of GIRmax). Secondary pharmacokinetic end points included AUC for serum insulin (AUCAsp,0–16min– AUCAsp,0–30min, AUCAsp,0–60min, AUCAsp,0–90min, AUCAsp,0–2h, and AUCAsp,0–8h), maximum insulin concentration (Cmax), time to Cmax (tmax), time to 50% of Cmax (tEarly50%Cmax and tLate50%Cmax), where tEarly and tLate are time to 50% of Cmax in the early and late part of the pharmacokinetic profile, respectively, and onset of appearance and time to disappearance (time from trial product administration until the last and last time serum insulin concentration was higher than or equal to LLOQ, respectively). Pharmacokinetic end points were assessed using baseline-corrected data, where the baseline value derived from the mean of all predose values was subtracted from insulin aspart values. After baseline correction, all negative values were set to zero. Secondary end points for safety included AEs, local tolerability, vital signs variation, electrocardiogram, and laboratory safety parameters.

Statistical Analysis
Sample size calculation was performed for the primary end point (AUCGIR,0–60min) and was based on the results of a previous trial that had evaluated the pharmacokinetics and pharmacodynamics of IAsp and faster IAsp (20). In the current trial, the mean treatment ratio (AT247-to-IAsp) was assumed to be equal to 1.31 with a coefficient of variation of 0.39. Thus, 18 completers were required to detect a treatment difference with a power of 80% (two-sided test, 5% level of significance). According to this calculation, 18 participants were planned to be randomized. To achieve 18 completers, up to 4 replacement participants could be enrolled to account for drop-outs. The replacement participants were assigned to the same treatment sequence as the drop-outs.

Statistical analyses of pharmacokinetic and pharmacodynamic end points were performed using SAS 9.4 (SAS Institute, Cary, NC) on an intention-to-treat basis including all randomized participants who had completed at least one dosing visit. Additionally, a per-protocol analysis was performed including all participants who completed all three dosing visits (data not shown). No interim analyses were conducted.

Study end points were compared between AT247 and both IAsp and faster IAsp using a linear mixed model for the log-transformed data, with treatment, treatment sequence, and visit as fixed effects and participant as a random effect. Least squares means, treatment ratios (AT247-to-IAsp, AT247-to-faster IAsp) and 95% CIs were calculated based on log-transformed data and back-transformed to the original scale. If a log transformation could not be performed due to zero values, or log-transformed data deviated from normality according to the Shapiro-Wilk test, untransformed parameters were analyzed by using the Koch adaptation of the Wilcoxon rank sum test for paired comparisons. The ratios of the treatment means (AT247-to-IAsp and AT247-to-faster IAsp) and their 95% CIs were calculated post hoc for all AUC end points using the Fieller method (28). The primary analysis results for AUC end points are provided in Supplementary Table 2. All data are presented as median (25th percentile; 75th percentile) or mean ± SD if not otherwise stated. Analyses of safety end points were performed descriptively, based on all participants who received at least one dose of AT247, IAsp, or faster IAsp.

RESULTS
Participant Disposition and Demographics
Participant disposition is provided in Supplementary Fig. 1. The trial was conducted between April and August 2019. A total of 27 individuals were screened, and 19 (including 18 participants and 1 replacement participant) were randomized and received trial products. Of these, 18 participants (95%) completed the trial. One participant withdrew consent after dosing visit 2 and was therefore replaced by a participant who was allocated to the same treatment sequence as the drop-out (Supplementary Fig. 1).

All randomized participants were Caucasian and had a mean ± SD age of
### Table 1

Onset, offset and overall exposure and glucose-lowering effect for a novel formulation of insulin aspart versus currently marketed insulin aspart formulations

| Parameter                                      | AT247* IAsp* | Faster IAsp* |
|------------------------------------------------|--------------|--------------|
| Onset of early exposure                        |              |              |
| Onset of appearance, min                       | 12.0 (11.0; 13.0) | 23.0 (21.0; 24.0) |
| Early50%Cmax, min                              | 30.0 (25.0; 37.0)  | 45.0 (40.0; 50.0) |
| tmax, min                                       | 50.0 (45.0; 55.0)  | 65.0 (60.0; 70.0) |
| Onset of glucose-lowering effect                |              |              |
| Onset of action, min                            | 17.0 (15.0; 19.0)  | 23.0 (21.0; 25.0) |
| t50%GIRmax, min                                 | 30.0 (25.0; 35.0)  | 45.0 (40.0; 50.0) |
| GIRmax, min                                     | 95.0 (85.0; 105.0) | 130.0 (120.0; 140.0) |
| Offset of exposure and overall exposure         |              |              |
| tLate50%Cmax, min                              | 280.0 (260.0; 300.0) | 300.0 (280.0; 320.0) |
| t50%GIRmax, min                                 | 22.5 (20.0; 25.0)  | 25.0 (23.0; 27.0) |
| GIRmax, mg/kg/min                               | 9.1 (5.2; 12.7)   | 8.0 (6.3; 10.5) |

#### Notes:
- Data are presented as median (25th percentile; 75th percentile) or geometric mean ± 95% CI.
- Treatment differences (treatment comparison calculated using the Wilcoxon rank sum test using untransformed parameters) between treatment arms are presented as median (25th percentile; 75th percentile) or geometric mean ± 95% CI.
- Time to disappearance, min: 47.7 (39.0; 51.0) 40.0 (32.0; 47.0)
- Time to disappearance: 47.7 (39.0; 51.0) 40.0 (32.0; 47.0)
- Time to appearance: 17.3 (15.0; 20.0) 17.3 (15.0; 20.0)

#### Statistical Analysis:
- Median treatment difference (treatment comparison calculated using the Wilcoxon rank sum test using untransformed parameters).
- Mean treatment ratios (95% CI) are presented for Cmax (log-transformed data analyzed by means of a mixed-effects model and results back-transformed to the original scale).

#### Additional Information:
- Cmax, mU/L
  - AT247*: 118.2 ± 6.5
  - Faster IAsp*: 122.0 ± 6.4
  - Mean treatment ratios (95% CI): 1.15 (0.99; 1.33) 0.0595

---

Table 1—Onset of early exposure and glucose-lowering effect for a novel formulation of insulin aspart versus currently marketed insulin aspart formulations.
The mean body weight was 86.1 ± 6.6 kg, mean BMI was 27.2 ± 3.7 kg/m², mean duration of diabetes was 20.0 ± 11.1 years, mean fasting C-peptide level was 0.08 ± 0.17 ng/mL, mean HbA1c was 7.1 ± 0.7% (53.8 ± 7.7 mmol/mol), and mean fasting PG was 157 ± 55 mg/dL. At entry into the trial, 7 participants were receiving multiple daily injection insulin therapy, 11 were using insulin pump therapy, and 1 was treated with insulin pump therapy in combination with bolus insulin injection.

**Onset of Early Exposure and Glucose-Lowering Effect**

Results on primary and secondary end points are summarized in Table 1 and Supplementary Table 3. The pharmacokinetic and pharmacodynamic profiles of all trial products are shown in Fig. 1. Early insulin exposure was significantly left-shifted for AT247 compared with IAsp and faster IAsp. Onset of appearance of AT247 occurred 2 min after administration, which was 12 and 2 min earlier than for IAsp and faster IAsp, respectively. Furthermore, t_{Early50%Cmax} and t_{max} were decreased from 38 and 90 min (IAsp) and from 24 and 75 min (faster IAsp) to 12 and 50 min when AT247 was injected. Uncorrected total insulin concentration-time profiles revealed similar differences in key end points (Supplementary Fig. 3) that did not significantly differ from insulin aspart data (t_{Early50%Cmax} and t_{max} in Table 1).

Likewise, GIR profiles were left-shifted for AT247 compared with IAsp and faster IAsp (Fig. 1), with a significant earlier onset of action (23 and 9 min earlier than for IAsp and faster IAsp, respectively). While t_{Early50%Cmax} was significantly accelerated for AT247 compared with both insulin aspart reference formulations, t_{max} took place significantly earlier compared with IAsp, whereas no statistical difference compared with faster IAsp was observed.

In addition, a higher early insulin exposure and larger glucose-lowering effect up to 2 h after dosing was observed for AT247, as illustrated in Fig. 2 (data listed in Supplementary Table 3). The primary end point AUC_{GIR,0–60min} was significantly enhanced for AT247 compared with IAsp and faster IAsp. Insulin exposure within the first 16 min after dosing (AUC_{Asp,0–16min}) was accelerated 12 and 3 times for AT247 compared with IAsp and faster IAsp, respectively. Within...
the first 30 min, 5 times higher insulin exposure (AUC_{Asp,0–30min}) and 12 times higher glucose-lowering effect (AUC_{GIR,0–30min}) were observed for AT247 than for IAsp, and 2 times higher AUC_{Asp,0–90min} and 3 times higher AUC_{GIR,0–30min} than for faster IAsp.

Offset and Overall Exposure and Glucose-Lowering Effect
Offset of exposure, measured by $t_{\text{Late 50% GI}}$, occurred 32 and 27 min earlier for AT247 than for IAsp and faster IAsp, respectively. Time to disappearance of insulin aspart did not significantly differ between AT247 and IAsp but was significantly faster (23 min) compared with faster IAsp. Duration of glucose-lowering effect for AT247, measured by $t_{\text{Late 50% GI}}$, was similar to both IAsp and faster IAsp (Table 1). Moreover, overall insulin exposure (AUC_{Asp,0–8h}) and C_{max} were similar for all three trial products as was the overall glucose-lowering effect (AUC_{GIR,0–8h}) and GIR_{max} (Table 1 and Supplementary Table 3).

Safety
AT247, IAsp, and faster IAsp were well tolerated, and no clinically relevant findings were made in physical examinations, vital sign measures, electrocardiograms, and safety clinical laboratory evaluations. A total of 13 participants (68%) reported 31 AEs, which were mild to moderate in intensity and assessed as unlikely to be related to trial product administration. Only two events (nausea and injection site reaction) were considered to be treatment related, both after administration of faster IAsp. They were, however, considered mild, and the participants recovered with no action to trial product taken.

CONCLUSIONS
This is the first study to investigate the pharmacokinetics, pharmacodynamics, and safety of AT247 compared with currently marketed insulin aspart formulations (IAsp and faster IAsp) in people with type 1 diabetes. The pharmacokinetic and pharmacodynamic profiles were both left-shifted for AT247 relative to IAsp and faster IAsp profiles, and AT247 was well tolerated with no safety concerns.

Our pharmacological data within the first 2 h postdose obtained for IAsp and faster IAsp were in line with previously published individual clamp studies (20,29,30) and pooled analyses of clinical trials comparing their pharmacological properties (31–33) in type 1 diabetes. The results of the current study demonstrate that AT247 not only provides accelerated onset, exposure, and glucose-lowering properties compared with standard of care insulin aspart (IAsp) but also exceeds the fastest available prandial insulin aspart (faster IAsp). A faster absorption and earlier insulin exposure compared with IAsp and faster IAsp has recently been reported for the insulin lispro analogs BioChaperone Lispro (17) and URLi (34).

Similarly to these second-generation insulin analogs, AT247 exhibited a faster offset of exposure by a left-shift of the late part of the pharmacokinetic time profile compared with IAsp and faster IAsp. The accelerated clearance of faster IAsp versus IAsp has already been well described (31,32). These reports showed that offset of faster IAsp was 12 min earlier than for IAsp ($P < 0.001$), which is consistent with our results. Compared with faster IAsp, AT247 resulted in a significantly further shortening of $t_{\text{Late 50% GI}}$ by 27 min. The duration of the glucose-lowering effect, measured by $t_{\text{Late 50% GI}}$, has been reported to be 14 min earlier for faster IAsp versus IAsp ($P < 0.001$) (31,32). In the current study, however, the mean differences in $t_{\text{Late 50% GI}}$, of 22 and 20 min comparing AT247 to IAsp and faster IAsp, respectively, were both not statistically significant. This may be attributed to the lower number of participants in the current trial. In addition, further meal challenge studies are needed to better understand the effect of an accelerated offset of exposure of AT247 in the prevention of late postprandial hypoglycemia. Similarity was observed between AT247, IAsp, and faster IAsp in overall insulin exposure and overall glucose-lowering effect. This is also in accordance with the results of the pooled pharmacological analyses of faster IAsp versus IAsp (31,32) and
confirms that the glucose-lowering potency is maintained and that only the time-concentration and time-action profiles are favorably changed.

In terms of safety, AT247 was well tolerated, and no safety concerns occurred during this single injection trial. The trial products contained insulin aspart as the active ingredient, which is considered safe based on >10 years of clinical experience (35). After a single injection of AT247, the insulin onset accelerator and stabilizer in the novel formulation did not show any negative impact on safety and tolerability; however, long-term safety needs to be confirmed.

The goal of developing second-generation insulin analogs is to overcome current difficulties and pitfalls in postprandial glycemic control. A large number of people with type 1 diabetes still struggle with correct dosing based on carbohydrate meal content, postprandial hyperglycemia, late postprandial hypoglycemia (36), timing of prandial insulin injections (13), handling of hyperglycemia corrections, or appropriate dosing for meals with a high glycemic index. Faster IAsp with its enhanced pharmacological properties partly covers these unmet needs, as shown in a range of phase 3 trials (32,35,37–40). In these trials, faster IAsp demonstrated superior postprandial glucose control accompanied with comparable or slightly improved overall glucose control and comparable risk for hypoglycemia. The even more accelerated pharmacokinetic profile of URLi has led to a further, however not statistically significant, reduction in postprandial glucose excursions compared with faster IAsp (34). Although the data on second-generation prandial insulin analogs such as AT247 are encouraging, their potential benefits for clinical practice still need to be proved (15). It is currently assumed that the benefits of faster insulin formulations will evolve from advances in closed-loop insulin delivery, with a closed-loop algorithm adjusted to the faster action profile (24,34).

A strength of the study was its randomized, double-blind, crossover design with sufficient time to allow for insulin washout. The study population of men with type 1 diabetes was homogenous, and endogenous insulin production as a confounding factor was controlled by including C-peptide-negative participants only. The euglycemic clamp design, which is considered as the gold standard for evaluating the glucose-lowering effect of exogenous insulins (9,41), ensured comparability with other pharmacological trials (32). Based on the low coefficient of PG variability during the euglycemic clamps, the clamp quality is considered high (26) and was furthermore comparable among all trial products (Supplementary Fig. 2 and Supplementary Table 1). Although all PG values were within the clamp target range, an increase in PG was observed after insulin dosing, which was most pronounced for IAsp, followed by faster IAsp and AT247. A post hoc analysis of the data showed that this has led to an underestimation of onset of action for all three trial products, but particularly for IAsp, and consequently to an overestimation of the differences between AT247 and both reference products. However, even when considering the PG increase in the calculation of onset of action, the differences between the treatments remain significant (Supplementary Table 4).

When interpreting the results of the study, the following potential limitations have to be taken into account. There is limited generalizability of our findings to the general population of people with diabetes because the study population comprised only men with type 1 diabetes who were on average overweight. Our restriction to male participants was based on regulatory recommendations for early-phase pharmacological studies, given that insulin sensitivity in women may vary during the menstrual cycle, and whether this may affect study results is unclear (42). The study did not address dose-concentration and dose-action relationships, because only one clinically relevant dose was administered. A further limitation concerns the clamp setting, which was designed to identify potential differences between the insulin aspart formulations rather than mimic real-life conditions such as basal insulin dosing, clinically relevant and personalized bolus doses, variable dietary habits, solid mixed meals, and physical activity. To fully explore the benefits of AT247 for clinical practice, further studies are needed to assess efficacy and safety in a larger and more balanced study population and to investigate the effect on postprandial and overall glucose control in real-world settings.

In conclusion, this first-in-man study with a novel insulin aspart formulation consistently demonstrates accelerated pharmacokinetic and pharmacodynamic profiles for AT247, with earlier insulin appearance, exposure, and offset in combination with enhanced early glucose-lowering effect compared with IAsp and faster IAsp. No relevant safety findings occurred during the trial. These results suggest that AT247 represents a promising candidate in the pursuit for second-generation prandial insulin analogs to improve postprandial glycemic control in people with diabetes.

Acknowledgments. The authors thank all of the participants and study site staff members involved in the trial. Furthermore, the authors acknowledge Andrea Berghold and Regina Riedl (Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria) for assistance with randomization, Hubert Scharngal (Clinical Institute for Medical and Chemical Laboratory Diagnosis, Medical University of Graz, Graz, Austria) for clinical laboratory analysis of safety parameters, and Karin Pickl (Joanneum Research Forschungsgesellschaft mbH, HEALTH – Institute for Biomedicine and Health Sciences, Graz, Austria) for quality assurance of laboratory measurements, data management, and statistical analysis.

Duality of Interest. This study was funded by Arecor Limited, U.K. D.G., J.J., S.H., L.Z., and F.L. are employees of Arecor Limited. T.R.P. has received research support from AstraZeneca and Novo Nordisk and has served on advisory panels for Adocia, Arecor, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk, and Roche Diabetes Care. No other potential conflicts of interest relevant to this article were reported.

The funding source had no role during the execution of the trial, and in data collection and analyses.

Author Contributions. E.S. and I.M. were the medical specialists of this clinical study. E.S., I.M., T.A., C.M., D.S., M.R., M.W., M.U., B.T., and F.F. contributed to data analysis. E.S., I.M., T.A., C.G., and T.R.P. contributed to data interpretation. E.S., I.M., D.S., M.W., and M.U. conducted the trial and contributed to data collection. E.S., T.A., D.G., J.J., S.H., L.Z., F.L., and T.R.P. contributed to the trial concept and design. E.S., T.A., D.G., M.R., C.G., F.L., and T.R.P. edited the manuscript. T.A. was responsible for statistics. C.M. and M.R. performed laboratory analyses. C.G. wrote the manuscript. All authors reviewed the manuscript and approved the final version for submission. T.R.P. was the principle investigator of the trial. T.R.P. is the guarantor, and as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the analysis.

Prior Presentation. Parts of this study were presented in oral abstract form at the virtual meeting on “Insulin Therapies” at the 80th Scientific Sessions of the American Diabetes Association, 12–16 June 2020, and at the virtual 56th Annual Meeting of the European Association for the Study of Diabetes, 21–25 September 2020.
euglycemic clamp study. Diabetes Obes Metab 2019;21:1086–1070.
18. Linnebjerg H, Zhang Q, LaBell E, et al. Pharmacokinetics and glucodynamics of ultra rapid lispro (URLI) versus Humalog® (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: a randomised controlled trial. Clin Pharmacokinet. 29 May 2020 [Epub ahead of print]. DOI: 10.1007/s40262-020-00903-0
19. Leor J, Deliva MA, Coutant DE, et al. Pharmacokinetics and glucodynamics of ultra rapid lispro (URLI) versus Humalog® (lispro) in patients with type 2 diabetes mellitus: a phase I randomised, crossover study. Clin Pharmacokinet. 29 May 2020 [Epub ahead of print]. DOI: 10.1007/s40262-020-00901-2
20. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 2015;17:682–688.
21. Pieber TR, Svehlikova E, Brunner M, Halberg IB, Due Thomsen KM, Haahr H. Faster-acting insulin aspart in people with type 2 diabetes: earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. Diabetes Obes Metab 2019;21:2068–2075.
22. Evans M, Wilkinson M, Giannopoulou A. Fast-acting insulin aspart: the rationale for a new mealtime insulin. Diabetes Ther 2019;10:1793–1800.
23. Evans M, Ceriello A, Danne T, et al. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab 2019;21:2039–2047.
24. Dovc K, Piona C, Yeniltepe Mutlu G, et al. Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial. Diabetes Care 2020;43:29–36.
25. Caillé F, Laverty R, Cadherin mechanics and complexation: the importance of calcium binding. Biophys J 2005;89:3895–3903.
26. Benesch E, Heise T, Klein O, Heinemann L, Arnolds S. How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device. J Diabetes Sci Technol 2015;9:792–800.
27. Seaquist ER, Anderson J, Childs B, et al.; American Diabetes Association; Endocrine Society. Hypoglycemia and diabetes: a report of a workshop of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013;98:1845–1859.
28. Fieller EC. Some problems in interval estimation. J R Stat Soc Ser B 1954;16:175–185.
29. Heise T, Stender-Petersen K, Hövelmann U, et al. Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet 2017;56:649–660.
30. Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging 2017;34:29–38.